On November 16, 2026, the FDA approved Roche's oral breast cancer pill Wilserdly (giredestrant) for patients with advanced HR-positive, HER2-negative cancer exhibiting ESR1 gene mutations. Clinical trial data showed Wilserdly slowed tumor progression by a median of 4.5 months compared to standard therapy. The approval strengthens Roche's oncology footprint, with analysts projecting annual peak sales between $2.5 billion and $14.5 billion.
FDA approval details and trial results
- ▪Wilserdly is approved for daily oral administration in combination with a targeted therapy for patients whose cancer progressed or recurred following prior therapy
- ▪The FDA approved Wilserdly after the drug slowed median cancer progression by 4.5 months compared to an older treatment combination
- ▪The FDA approved Roche Holding AG's oral breast cancer pill Wilserdly for patients with locally advanced or metastatic HR-positive, HER2-negative breast cancer
Wilserdly dosing and safety warnings
- ▪Wilserdly carries warning labels for bradycardia, a dangerously slow heart rate, and fetal toxicity in pregnant women
- ▪Wilserdly is meant to be taken once daily until the disease worsens or the patient develops unacceptable toxic complications
Mechanism of action and ESR1 mutations
- ▪Wilserdly, also known as giredestrant, is a selective estrogen receptor degrader designed to treat tumors driven by ESR1 gene mutations
- ▪ESR1 gene mutations indicate that an estrogen receptor-positive breast tumor is developing resistance to standard therapies
Commercial outlook and market reaction
- ▪Roche Holding AG's American depositary receipts increased by 1.2% in New York following the FDA approval of Wilserdly on November 16, 2026
- ▪Roche Holding AG has stated that Wilserdly could become Roche's top-selling product ever
- ▪Analysts forecast peak annual sales for Wilserdly ranging from $2.5 billion to $14.5 billion
Impact on Roche's oncology position
- ▪The approval of Wilserdly expands Roche Holding AG's footprint in an emerging class of medicines aimed at reshaping treatment for HR-positive breast cancer
- ▪Although Roche Holding AG historically established a major presence in breast cancer through Herceptin via Genentech, it had fallen behind rival pharmaceutical firms in oncology in recent years
Story comments
Loading comments…